Adeno-associated Virus-Mediated Gene Delivery Across the Blood-Brain Barrier

Overview

Journal Adv Neurobiol

Publisher Springer

Date 2024 Nov 26

PMID 39589711

Authors

Yizheng Yao

Fengfeng Bei

Affiliations

Soon will be listed here.

Abstract

Recombinant adeno-associated viruses (AAVs) have emerged as a popular tool for gene therapy in the central nervous system (CNS). Given the dense vasculature in the CNS, systemic administration is an appealing approach for achieving a broad distribution of AAV vectors across the CNS. However, the blood-brain barrier (BBB) is a major obstacle that blocks the entry of AAV vectors into the brain and spinal cord. Thus, there is a great need to develop novel AAV vector technology with enhanced BBB penetration. In this chapter, we briefly summarize AAV biology, possible mechanisms for AAV vectors to overcome the BBB and further engineering strategies, and current clinical trials using systemic AAV gene therapy for CNS diseases.

References

Abbott N, Ronnback L, Hansson E . Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2005; 7(1):41-53. DOI: 10.1038/nrn1824. View

Abbott N, Patabendige A, Dolman D, Yusof S, Begley D . Structure and function of the blood-brain barrier. Neurobiol Dis. 2009; 37(1):13-25. DOI: 10.1016/j.nbd.2009.07.030. View

Akache B, Grimm D, Pandey K, Yant S, Xu H, Kay M . The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol. 2006; 80(19):9831-6. PMC: 1617255. DOI: 10.1128/JVI.00878-06. View

Alonso A, Reinz E, Leuchs B, Kleinschmidt J, Fatar M, Geers B . Focal Delivery of AAV2/1-transgenes Into the Rat Brain by Localized Ultrasound-induced BBB Opening. Mol Ther Nucleic Acids. 2013; 2:e73. PMC: 3586801. DOI: 10.1038/mtna.2012.64. View

ATCHISON R, CASTO B, HAMMON W . ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES. Science. 1965; 149(3685):754-6. DOI: 10.1126/science.149.3685.754. View

Balague C, Kalla M, Zhang W . Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol. 1997; 71(4):3299-306. PMC: 191468. DOI: 10.1128/JVI.71.4.3299-3306.1997. View

Bell C, Vandenberghe L, Bell P, Limberis M, Gao G, Van Vliet K . The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest. 2011; 121(6):2427-35. PMC: 3104778. DOI: 10.1172/JCI57367. View

Bevan A, Duque S, Foust K, Morales P, Braun L, Schmelzer L . Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther. 2011; 19(11):1971-80. PMC: 3222525. DOI: 10.1038/mt.2011.157. View

Burger C, Gorbatyuk O, Velardo M, Peden C, Williams P, Zolotukhin S . Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther. 2004; 10(2):302-17. DOI: 10.1016/j.ymthe.2004.05.024. View

10.

Cardoso F, Brites D, Brito M . Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev. 2010; 64(2):328-63. DOI: 10.1016/j.brainresrev.2010.05.003. View

11.

Carman A, Mills J, Krenz A, Kim D, Bynoe M . Adenosine receptor signaling modulates permeability of the blood-brain barrier. J Neurosci. 2011; 31(37):13272-80. PMC: 3328085. DOI: 10.1523/JNEUROSCI.3337-11.2011. View

12.

Carrano A, Hoozemans J, van der Vies S, van Horssen J, de Vries H, Rozemuller A . Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy. Neurodegener Dis. 2012; 10(1-4):329-31. DOI: 10.1159/000334916. View

13.

Cearley C, Wolfe J . Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther. 2006; 13(3):528-37. DOI: 10.1016/j.ymthe.2005.11.015. View

14.

Chan K, Jang M, Yoo B, Greenbaum A, Ravi N, Wu W . Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci. 2017; 20(8):1172-1179. PMC: 5529245. DOI: 10.1038/nn.4593. View

15.

Choi J, Pernot M, Brown T, Small S, Konofagou E . Spatio-temporal analysis of molecular delivery through the blood-brain barrier using focused ultrasound. Phys Med Biol. 2007; 52(18):5509-30. DOI: 10.1088/0031-9155/52/18/004. View

16.

Colon-Thillet R, Jerome K, Stone D . Optimization of AAV vectors to target persistent viral reservoirs. Virol J. 2021; 18(1):85. PMC: 8067653. DOI: 10.1186/s12985-021-01555-7. View

17.

Davidson B, Stein C, Heth J, Martins I, Kotin R, Derksen T . Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A. 2000; 97(7):3428-32. PMC: 16256. DOI: 10.1073/pnas.97.7.3428. View

18.

Deverman B, Pravdo P, Simpson B, Kumar S, Chan K, Banerjee A . Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol. 2016; 34(2):204-9. PMC: 5088052. DOI: 10.1038/nbt.3440. View

19.

Deverman B, Ravina B, Bankiewicz K, Paul S, Sah D . Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov. 2018; 17(10):767. DOI: 10.1038/nrd.2018.158. View

20.

Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar A . Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther. 2009; 17(7):1187-96. PMC: 2835208. DOI: 10.1038/mt.2009.71. View